PLATELET-ACTIVATING-FACTOR PRIMES HUMAN EOSINOPHIL GENERATION OF SUPEROXIDE

被引:14
作者
ZORATTI, EM [1 ]
SEDGWICK, JB [1 ]
BATES, ME [1 ]
VRTIS, RF [1 ]
GEIGER, K [1 ]
BUSSE, WW [1 ]
机构
[1] UNIV WISCONSIN,SCH MED,DEPT MED,ALLERGY & IMMUNOL SECT,MADISON,WI 53706
关键词
D O I
10.1165/ajrcmb/6.1.100
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Platelet-activating factor (PAF) is a potent inflammatory mediator that can cause airway obstruction and hyperresponsiveness; these processes are also associated with pulmonary eosinophilia, suggesting a link between these two events. Thus, PAF's interaction with eosinophils may provide a mechanism for airway damage. However. direct in vitro activation of eosinophils by PAF requires concentrations that are likely higher than those achieved in vivo. As a result. we investigated whether lower, more physiologic concentrations of PAF could prime eosinophils for subsequent activation to another receptor-stimulated factor, in this case formylmethionylleucylphenylalanine (FMLP). To test this hypothesis, eosinophils were preincubated (1 and 15 min) with low concentrations of PAF (1 x 10(-8) and 1 x 10(-10)M); this exposure to PAF resulted in enhanced generation of superoxide anion to FMLP stimulation. Moreover, similar concentrations of PAF decreased eosinophil density and increased expression of cell surface CR3 receptors. Finally, low, nonactivating concentrations of PAF (1 x 10(-10) to 1 x 10(-8) M) caused transient increases in eosinophil cytosolic free Ca2+ concentrations. Collectively, these responses are consistent with the hypothesis that short-term exposure to low concentrations of PAF primes eosinophils to cause an enhanced inflammatory response upon subsequent activation to another receptor agonist. The consequences of this PAF-associated phenomenon can produce an enhanced inflammatory response and airway injury.
引用
收藏
页码:100 / 106
页数:7
相关论文
共 46 条
[1]   INFLAMMATORY CHARACTERISTICS OF PLATELET ACTIVATING FACTOR (PAF-ACETHER) IN HUMAN-SKIN [J].
ARCHER, CB ;
PAGE, CP ;
PAUL, W ;
MORLEY, J ;
MACDONALD, DM .
BRITISH JOURNAL OF DERMATOLOGY, 1984, 110 (01) :45-50
[2]   ACCUMULATION OF INFLAMMATORY CELLS IN RESPONSE TO INTRACUTANEOUS PLATELET ACTIVATING FACTOR (PAF-ACETHER) IN MAN [J].
ARCHER, CB ;
PAGE, CP ;
MORLEY, J ;
MACDONALD, DM .
BRITISH JOURNAL OF DERMATOLOGY, 1985, 112 (03) :285-290
[3]   ACCUMULATION OF PLATELETS AND EOSINOPHILS IN BABOON LUNG AFTER PAF-ACETHER CHALLENGE - INHIBITION BY KETOTIFEN [J].
ARNOUX, B ;
DENJEAN, A ;
PAGE, CP ;
NOLIBE, D ;
MORLEY, J ;
BENVENISTE, J .
AMERICAN REVIEW OF RESPIRATORY DISEASE, 1988, 137 (04) :855-860
[4]   RELEASE OF PLATELET-ACTIVATING FACTOR (PAF-ACETHER) FROM ALVEOLAR MACROPHAGES BY THE CALCIUM IONOPHORE A 23187 AND PHAGOCYTOSIS [J].
ARNOUX, B ;
DUVAL, D ;
BENVENISTE, J .
EUROPEAN JOURNAL OF CLINICAL INVESTIGATION, 1980, 10 (06) :437-441
[5]   PLATELET-ACTIVATING FACTOR AND ASTHMA [J].
BARNES, PJ .
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 1988, 81 (01) :152-160
[6]   HUMAN-NEUTROPHILS INCREASE EXPRESSION OF C3BI AS WELL AS C3B RECEPTORS UPON ACTIVATION [J].
BERGER, M ;
OSHEA, J ;
CROSS, AS ;
FOLKS, TM ;
CHUSED, TM ;
BROWN, EJ ;
FRANK, MM .
JOURNAL OF CLINICAL INVESTIGATION, 1984, 74 (05) :1566-1571
[7]  
BRUYNZEEL PL, 1984, PHARMACOL RES COMMUN, V18, P61
[8]  
CUSS FM, 1986, LANCET, V2, P189
[9]  
DEMONCHY JGR, 1985, AM REV RESPIR DIS, V131, P373
[10]  
DETNERS PA, 1988, CURREN OPIN IMMUNOL, V1, P10